SCHEMBL3829454

SCHEMBL3829454

O=C(CN1CCN(CC(O)CC(=O)Nc2ccccc2F)CC1)Nc1ccc2[nH]ncc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.56
CHRNB4 P30926 1/20 0.56
CHRNA3 P32297 1/20 0.56
CHRNA4 P43681 1/20 0.56
ALDH1A1 P00352 7/20 0.52
KDM4E B2RXH2 2/20 0.52
MAPT P10636 2/20 0.51
TP53 P04637 1/20 0.51
ROCK2 O75116 4/20 0.49
GFER P55789 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
KMT2A Q03164 1/20 0.49
LMNA P02545 1/20 0.48
HTT P42858 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
ROCK1 Q13464 3/20 0.47
TSHR P16473 1/20 0.47
HSD17B10 Q99714 1/20 0.47
POLB P06746 1/20 0.46
JAK2 O60674 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4865890 0.84 CHRNB2 (0.56) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL3832557 0.83 MAPT (0.60) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL3831633 0.83 MAPT (0.65) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL3829146 0.81 MAPT (0.64) ALDH1A1KDM4EMAPTTP53GFER
SCHEMBL3831429 0.81 LMNA (0.58) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL4500886 0.81 ROCK2 (0.62) CHRNB2CHRNB4CHRNA3CHRNA4ROCK2
SCHEMBL3831622 0.80 ALDH1A1 (0.59) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL3828113 0.80 MAPT (0.58) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1
SCHEMBL3826743 0.79 MAPT (0.82) ALDH1A1KDM4EMAPTTP53GFER
SCHEMBL3833776 0.78 CYP2C19 (0.60) CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566717-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2009-07-28 US claimed
US-20080275238-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS PALLE VENKATA 2008-11-06 US claimed
EP-1578737-B1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS INC (US) 2009-09-16 EP disclosed
US-7566717-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2009-07-28 US disclosed
US-20080275238-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS PALLE VENKATA 2008-11-06 US disclosed
US-20070155728-A1 Substituted Heterocyclic Compounds PALLE VENKATA 2007-07-05 US disclosed
US-7205303-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2007-04-17 US disclosed
EP-1578737-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. (US) 2005-09-28 EP disclosed
US-20040176356-A1 Substituted heterocyclic compounds CV THERAPEUTICS, INC. 2004-09-09 US disclosed
WO-2004063180-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176356-A1 Substituted heterocyclic compounds KCNH1, KCNJ2, SCN5A CHRNB2 3835/4885CHRNB4 3499/4885CHRNA3 2532/4885
US-20080275238-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS KCNH1, SDHA, COQ8A CHRNB2 4017/4885CHRNB4 3260/4885CHRNA3 3120/4885
US-20070155728-A1 Substituted Heterocyclic Compounds KCNH1, SDHA, COQ8A CHRNB2 4017/4885CHRNB4 3260/4885CHRNA3 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.